Table 2.
Predictors of increased Raynaud's phenomenon intensity after monthly iloprost withdrawal.
| Worsened RP n = 11 |
Not worsened RP n = 39 |
p | |
|---|---|---|---|
| Female, n (%) | 11 (100.0) | 34 (87.2) | 0.211 |
| Age, years, mean ± SD | 54.6 ± 14.6 | 55.0 ± 13.2 | 0.942 |
| Disease duration, year, mean ± SD | 10.6 ± 8.0 | 11.4 ± 6.4 | 0.731 |
| Diffuse cutaneous, n (%) | 3 (27.3) | 12 (30.8) | 0.823 |
| Anticentromere antibodies, n (%) | 3 (27.3) | 10 (25.6) | 0.913 |
| Anti-Scl70 antibodies, n (%) | 4 (36.4) | 14 (35.9) | 0.977 |
| History of digital ulcers, n (%) | 20 (51.3) | 7 (63.6) | 0.468 |
| Current digital ulcers, n (%) | 8 (20.5) | 0 (0.0) | 0.101 |
| Scleroderma pattern early, n (%) | 4 (36.4) | 18 (46.2) | 0.563 |
| Scleroderma pattern active, n (%) | 4 (36.4) | 12 (30.8) | 0.725 |
| Scleroderma pattern late, n (%) | 3 (27.3) | 9 (23.1) | 0.774 |
| Giant capillaries, n (%) | 5 (45.5) | 19 (48.7) | 0.848 |
| Haemorrhages, n (%) | 5 (45.5) | 11 (28.2) | 0.279 |
| Avascular areas, n (%) | 6 (54.5) | 16 (54.5) | 0.425 |
| Neovascularization, n (%) | 4 (36.4) | 9 (23.1) | 0.375 |
| Average capillary density, capillaries/mm, mean ± SD | 5.4 ± 1.4 | 6.6 ± 1.7 | 0.028 |
| Lower capillary density, capillaries/mm, mean ± SD | 3.7 ± 1.2 | 4.6 ± 2.2 | 0.232 |
| Calcium channel blockers, n (%) | 6 (54.5) | 27 (69.2) | 0.364 |
| Anti-endothelin treatment, n (%) | 1 (9.1) | 4 (10.3) | 0.909 |
| Anti-PDE-5 treatment, n (%) | 0 (0.0) | 4 (10.3) | 0.268 |
| ASA 100 mg/die, n (%) | 6 (54.5) | 24 (61.5) | 0.676 |
| Decreased reported cold exposure, n (%) | 8 (72.7) | 18 (46.2) | 0.119 |
| Mood disorder under medical treatment, n (%) | 5 (45.5) | 6 (15.4) | 0.033 |
Abbreviations: RP Raynaud's phenomenon, SD standard deviation, ASA acetylsalicylic acid, PDE phosphodiesterase.